Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Marial + omeprazole** is a combination therapy used for the treatment of gastroesophageal reflux disease (GERD) and related conditions. Marial is a medical device formulation that typically includes magnesium alginate and the E-Gastryal complex (hyaluronic acid, hydrolyzed keratin, tara gum, xanthan gum, and purified water). It acts mechanically by forming a mucoadhesive film that adheres to the esophageal mucosa, providing a protective barrier against gastric acid, promoting healing, and reducing symptoms of acid reflux, heartburn, and mucosal injury. Omeprazole is a proton pump inhibitor (PPI), a small molecule drug that reduces gastric acid secretion by irreversibly blocking the H+/K+-ATPase enzyme (proton pump) on gastric parietal cells. This combination targets rapid and effective symptom control through complementary mechanisms—mechanical protection (Marial) and acid suppression (omeprazole)—and is evaluated particularly for patients with persistent reflux symptoms despite standard PPI therapy[1][2][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Marial + omeprazole.